41 results on '"Martínez-Martí A"'
Search Results
2. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
3. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
4. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
5. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
6. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
7. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials
8. P3.08E.01 Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival
9. MA01.08 Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer (NADIM Trial)
10. OA01.04 IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
11. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
12. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
13. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
14. EP14.04-02 Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients (p)
15. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials
16. EP07.04-01 Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results
17. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
18. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used
19. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)
20. EP08.01-078 Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors
21. EP07.01-023 Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)
22. EP07.01-022 Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)
23. PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
24. MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
25. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study
26. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy
27. 198P Analysis of efficacy of immunotherapy according to histology in malignant pleural mesothelioma (MPM) patients
28. 127P Real-world evidence and clinical characteristics in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI)
29. 126P Clinical predictive factors in real world setting in advanced non-small cell lung cancer (NSCLC) patients (pts)treated with immune checkpoint inhibitors (ICI)
30. 81P Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial
31. P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial
32. P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial
33. P24.06 Real World use of Cisplatin and Carboplatin Based Therapy in Patients with Malignant Pleural Mesothelioma (MPM)
34. FP12.09 Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients.
35. P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients
36. P1.16-05 Incidence and Outcome of Multiple Primary Cancers (MPC) in a Series of Lung Cancer (LC) Patients
37. OA13.05 NADIM Study: Updated Clinical Research and Outcomes
38. MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry
39. OA01.05 Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG
40. HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?
41. 219P Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.